Market Cap 777.08B
Revenue (ttm) 45.04B
Net Income (ttm) 10.59B
EPS (ttm) N/A
PE Ratio 50.31
Forward PE 35.54
Profit Margin 23.51%
Debt to Equity Ratio 2.24
Volume 2,211,100
Avg Vol 3,662,764
Day's Range N/A - N/A
Shares Out 946.46M
Stochastic %K 82%
Beta 0.47
Analysts Strong Sell
Price Target $921.33

Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncolog...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 317 276 2000
Address:
Lilly Corporate Center, Indianapolis, United States
BrunetteSara
BrunetteSara Oct. 25 at 3:10 AM
0 · Reply
TraderMark71
TraderMark71 Oct. 25 at 1:59 AM
$LLY $UPST $OUST $AMPX $SOUN Hey, 4 out of 5 wasn't too bad... SOUN will still recover... Give it a couple of weeks till earnings..
0 · Reply
resistancebreakers
resistancebreakers Oct. 24 at 6:54 PM
SHORT SQUEEZE call $LLY $ADVM it's gonna go MASSIVE 🔥🪖🫡☝️
0 · Reply
Lifestaylaluxuryy
Lifestaylaluxuryy Oct. 24 at 6:42 PM
$ASBP There are 1,054 of us here, including me. I can see everyone is quiet for now, but never forget—we are powerful together, and our strength is unstoppable. ✊ $PFE $LLY $NVO
1 · Reply
TalkMarkets
TalkMarkets Oct. 24 at 6:39 PM
#EliLilly And Co. Stock: Gains As $12.47-Per-Share Adverum Biotech Deal Expands Gene Therapy Portfolio $LLY https://talkmarkets.com/content/stocks--equities/eli-lilly-and-co-stock-gains-as-1247-per-share-adverum-biotech-deal-expands-gene-therapy-portfolio?post=530321
0 · Reply
derrdavid
derrdavid Oct. 24 at 5:47 PM
$LLY STO 10/31$820 put
0 · Reply
prismmarketview
prismmarketview Oct. 24 at 5:42 PM
(NYSE: $LLY),(NASDAQ: $ADVM) #EliLillyandCo is acquiring #adverumbio in a deal valued up to $262M. The buyout includes $3.56 per share in cash plus contingent value rights worth up to $8.91 per share, tied to regulatory and commercial milestones for Ixo-vec, a one-time gene therapy for wet age-related macular degeneration (wAMD). The acquisition strengthens Lilly’s pipeline in eye disease and gene therapy, with the deal expected to close Q4 2025. https://prismmarketview.com/eli-lilly-expands-gene-therapy-footprint-with-262m-acquisition-of-adverum-biotechnologies/
0 · Reply
2_logs_higher
2_logs_higher Oct. 24 at 5:40 PM
$AGEN & $INCY, $LLY INCY needs to buy needs to buy Agen LLY needs to buy INCY New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to <18) with severe alopecia areata (AA) achieve successful hair regrowth on the scalp, eyebrows and eyelashes at one year. Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial New data show 71% of adolescents with severe disease treated with baricitinib 4 mg achieved successful scalp hair regrowth at one year, with continuous improvements observed throughout those 52 weeks Lilly intends to submit the BRAVE-AA-PEDS data to global regulators for a potential label update for baricitinib (commercially available as Olumiant) https://finance.yahoo.com/news/lillys-baricitinib-delivered-near-complete-104500483.html?guccounter=1
1 · Reply
noofnoof1
noofnoof1 Oct. 24 at 5:35 PM
$NKTR Twitter user @unemon1 offered an interesting theory that $LLY might be in the acquisition process. Link to DD below. Thoughts? https://unemon.com/ResearchEasy/202510_NKTR/20251022_NKTR_LLY.html
1 · Reply
LastResort
LastResort Oct. 24 at 4:39 PM
$VKTX follow the people, not just the pipeline We have good data, the corporate geometry between Viking and Lilly is getting harder to ignore. Viking’s VP of Finance, Michael Morneau, previously ran Finance at Lilly Research Labs. That kind of familiarity matters, it makes diligence and integration smoother if discussions ever start. Then there’s geography. Lilly’s new Gateway Labs metabolic R&D hub in Torrey Pines sits just minutes from Viking’s HQ in Pacific Heights. If Lilly wanted a SoCal obesity beachhead, this is exactly how you’d design it, close enough to share talent, vendors, and infrastructure without disruption. Meanwhile, the Street keeps pairing Viking with Lilly and Novo as the next obesity contender — or potential target. Fierce Biotech and others have echoed the same idea. Same city, same therapeutic lane, overlapping leadership. At some point, that starts to look like more than coincidence. #GLP1 #Obesity #Biotech #MNA $VKTX $LLY
2 · Reply
Latest News on LLY
Eli Lilly: Time To Buy LLY Stock?

Oct 24, 2025, 10:07 AM EDT - 16 hours ago

Eli Lilly: Time To Buy LLY Stock?


Lilly to Acquire Adverum Biotechnologies

Oct 24, 2025, 8:30 AM EDT - 18 hours ago

Lilly to Acquire Adverum Biotechnologies

ADVM


My Top 3 Pharma Stocks

Oct 20, 2025, 11:38 AM EDT - 4 days ago

My Top 3 Pharma Stocks

AKRO BMY ETNB MRK NVO PFE SPY


President Trump targets $150 MFN price for GLP-1s

Oct 17, 2025, 7:32 PM EDT - 7 days ago

President Trump targets $150 MFN price for GLP-1s

NVO


3 Price Catalysts For Eli Lilly

Oct 17, 2025, 4:26 PM EDT - 7 days ago

3 Price Catalysts For Eli Lilly


How LLY Stock Delivered $47 Billion To Shareholders

Oct 15, 2025, 9:50 AM EDT - 9 days ago

How LLY Stock Delivered $47 Billion To Shareholders


Eli Lilly: The Rally Has More Room To Run (Rating Upgrade)

Oct 13, 2025, 10:51 AM EDT - 11 days ago

Eli Lilly: The Rally Has More Room To Run (Rating Upgrade)


Buy LLY Stock At $820?

Oct 3, 2025, 8:35 AM EDT - 21 days ago

Buy LLY Stock At $820?


Why Eli Lilly Is The Lion's Share Of My Portfolio

Oct 2, 2025, 11:26 PM EDT - 22 days ago

Why Eli Lilly Is The Lion's Share Of My Portfolio


ABBV Stock vs. Eli Lilly & Merck

Oct 2, 2025, 8:20 AM EDT - 22 days ago

ABBV Stock vs. Eli Lilly & Merck

ABBV MRK


BrunetteSara
BrunetteSara Oct. 25 at 3:10 AM
0 · Reply
TraderMark71
TraderMark71 Oct. 25 at 1:59 AM
$LLY $UPST $OUST $AMPX $SOUN Hey, 4 out of 5 wasn't too bad... SOUN will still recover... Give it a couple of weeks till earnings..
0 · Reply
resistancebreakers
resistancebreakers Oct. 24 at 6:54 PM
SHORT SQUEEZE call $LLY $ADVM it's gonna go MASSIVE 🔥🪖🫡☝️
0 · Reply
Lifestaylaluxuryy
Lifestaylaluxuryy Oct. 24 at 6:42 PM
$ASBP There are 1,054 of us here, including me. I can see everyone is quiet for now, but never forget—we are powerful together, and our strength is unstoppable. ✊ $PFE $LLY $NVO
1 · Reply
TalkMarkets
TalkMarkets Oct. 24 at 6:39 PM
#EliLilly And Co. Stock: Gains As $12.47-Per-Share Adverum Biotech Deal Expands Gene Therapy Portfolio $LLY https://talkmarkets.com/content/stocks--equities/eli-lilly-and-co-stock-gains-as-1247-per-share-adverum-biotech-deal-expands-gene-therapy-portfolio?post=530321
0 · Reply
derrdavid
derrdavid Oct. 24 at 5:47 PM
$LLY STO 10/31$820 put
0 · Reply
prismmarketview
prismmarketview Oct. 24 at 5:42 PM
(NYSE: $LLY),(NASDAQ: $ADVM) #EliLillyandCo is acquiring #adverumbio in a deal valued up to $262M. The buyout includes $3.56 per share in cash plus contingent value rights worth up to $8.91 per share, tied to regulatory and commercial milestones for Ixo-vec, a one-time gene therapy for wet age-related macular degeneration (wAMD). The acquisition strengthens Lilly’s pipeline in eye disease and gene therapy, with the deal expected to close Q4 2025. https://prismmarketview.com/eli-lilly-expands-gene-therapy-footprint-with-262m-acquisition-of-adverum-biotechnologies/
0 · Reply
2_logs_higher
2_logs_higher Oct. 24 at 5:40 PM
$AGEN & $INCY, $LLY INCY needs to buy needs to buy Agen LLY needs to buy INCY New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to <18) with severe alopecia areata (AA) achieve successful hair regrowth on the scalp, eyebrows and eyelashes at one year. Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial New data show 71% of adolescents with severe disease treated with baricitinib 4 mg achieved successful scalp hair regrowth at one year, with continuous improvements observed throughout those 52 weeks Lilly intends to submit the BRAVE-AA-PEDS data to global regulators for a potential label update for baricitinib (commercially available as Olumiant) https://finance.yahoo.com/news/lillys-baricitinib-delivered-near-complete-104500483.html?guccounter=1
1 · Reply
noofnoof1
noofnoof1 Oct. 24 at 5:35 PM
$NKTR Twitter user @unemon1 offered an interesting theory that $LLY might be in the acquisition process. Link to DD below. Thoughts? https://unemon.com/ResearchEasy/202510_NKTR/20251022_NKTR_LLY.html
1 · Reply
LastResort
LastResort Oct. 24 at 4:39 PM
$VKTX follow the people, not just the pipeline We have good data, the corporate geometry between Viking and Lilly is getting harder to ignore. Viking’s VP of Finance, Michael Morneau, previously ran Finance at Lilly Research Labs. That kind of familiarity matters, it makes diligence and integration smoother if discussions ever start. Then there’s geography. Lilly’s new Gateway Labs metabolic R&D hub in Torrey Pines sits just minutes from Viking’s HQ in Pacific Heights. If Lilly wanted a SoCal obesity beachhead, this is exactly how you’d design it, close enough to share talent, vendors, and infrastructure without disruption. Meanwhile, the Street keeps pairing Viking with Lilly and Novo as the next obesity contender — or potential target. Fierce Biotech and others have echoed the same idea. Same city, same therapeutic lane, overlapping leadership. At some point, that starts to look like more than coincidence. #GLP1 #Obesity #Biotech #MNA $VKTX $LLY
2 · Reply
BarkingPuppy
BarkingPuppy Oct. 24 at 4:27 PM
$ELTP $PFE $JNJ $LLY Branded Pipeline Programs Under Development Therapeutic Category Development Stage SequestOxTM (ELI-200) Opioid-Pain-NDA Submitted Pending Approval. Which one of the Big Boys are going to snatch-up Elite before SequestOx gets approved. I bought stake in all so I win no matter what. The People who really win are We The People. Elite's SequestOx is a game changer for the World. There is no public information indicating that Elite Pharmaceuticals is being bought by a specific company. While there are recent reports of insider buying by a specific individual and strong financial performance, the company has not announced any acquisition plans.
1 · Reply
biolover
biolover Oct. 24 at 3:40 PM
$VKTX Rumor is $VKTX already finished accrual for Vanquish 1 Should hear an announcement next few days. ? Thousands more than FDA requirement $LLY $NVO
0 · Reply
ZacksResearch
ZacksResearch Oct. 24 at 3:13 PM
$LLY: Can Eli Lilly’s oncology growth offset GLP-1 reliance? 💥 🔬 Oncology segment projected to grow over 15% YoY in Q3 💊 Demand for Verzenio bolsters confidence 📈 Shares outperforming industry YTD despite high P/E Opportunity assessment here 👉 https://www.zacks.com/stock/news/2776275/heres-how-eli-lillys-oncology-drugs-are-poised-ahead-of-q3-earnings?cid=sm-stocktwits-2-2776275-body-17507&ADID=SYND_STOCKTWITS_TWEET_2_2776275_BODY_17507
0 · Reply
Bullish_Trader555
Bullish_Trader555 Oct. 24 at 2:44 PM
0 · Reply
FrankDeux
FrankDeux Oct. 24 at 2:42 PM
$LLY coiling up, really? Noice
0 · Reply
AKvf
AKvf Oct. 24 at 2:21 PM
Amid boardroom chaos and a brutal stock selloff, $NVO may have just made a brilliant move, says HC Andersen Capital’s head of equities Michael Friis Jørgensen. The company has hired Michael Novod, one of the world’s most respected Novo Nordisk analysts, away from Nordea to become its new Head of Investor Relations. Michael Friis Jørgensen calls it “a genius move,” noting that Michael Novod knows global investors well and can help rebuild confidence as fears grow that rival $LLY could dominate the obesity drug market. Michael Novod recently set a price target of DKK 583 for Novo, implying roughly 74% upside. He joins the company in spring 2026 as SVP and Head of Investor Relations after 15 years at Nordea.
1 · Reply
ZacksResearch
ZacksResearch Oct. 24 at 2:13 PM
$LLY gearing up for a big Q3 test — can its oncology lineup deliver the next growth leg? Analysts are watching closely as Eli Lilly’s cancer drugs take center stage ahead of earnings, with expectations building around their performance and pipeline momentum. Full pre-earnings breakdown here 👉 https://www.zacks.com/stock/news/2776275/heres-how-eli-lillys-oncology-drugs-are-poised-ahead-of-q3-earnings?cid=sm-stocktwits-2-2776275-teaser-17500&ADID=SYND_STOCKTWITS_TWEET_2_2776275_TEASER_17500
0 · Reply
BesTrades1
BesTrades1 Oct. 24 at 2:11 PM
$ADVM bought 1000 shares, if $LLY wants it, I want it too.
0 · Reply
Bullish_Trader555
Bullish_Trader555 Oct. 24 at 2:09 PM
$MRUS Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety – 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) - $SPY $LLY $REGN
0 · Reply
Keepitmoving
Keepitmoving Oct. 24 at 2:06 PM
$LLY I’m hoping for positive fireworks next Thursday during earnings. Tirzepatide should be ripping hard 🚀
0 · Reply
topstockalerts
topstockalerts Oct. 24 at 2:04 PM
Adverum Biotechnologies shares rose after Eli Lilly announced its acquisition of the clinical-stage gene therapy company. The deal values Adverum at $3.56 per share in cash, plus a contingent value right (CVR) offering up to $8.91MORE per share based on milestones, with a total potential value of $12.47 per share. Despite the surge, Adverum's stock closed at $4.90, below the potential maximum value. Lilly will gain control of Adverum's lead product, Ixo-vec, a Phase 3 gene therapy for age-related wet macular degeneration (wAMD), aiming to replace repeated injections with a single dose. CVR payments are tied to U.S. approval and sales milestones. Lilly will also provide up to $65 million in funding for Adverum's ongoing trials before the deal closes in Q4 2025. The acquisition supports Lilly's strategy to expand its genetic medicine capabilities in age-related diseases. $ADVM $LLY
0 · Reply
biotech
biotech Oct. 24 at 2:01 PM
$ADVM Gene therapy buyout by $LLY $SGMO buyout by Astellas ? is NEXT ! as early as monday IMHO
0 · Reply